宫颈癌的临床病理与分子标志物:一项前瞻性队列研究
该研究在401例宫颈癌患者的前瞻性队列中验证临床病理特征,并对292例癌组织进行p53和HER2免疫组化检测。结果显示血管间隙侵犯、组织学类型和肿瘤大小是强独立预后标志物,高p53蛋白水平独立预测较差生存但不反映TP53突变状态,ERBB2扩增与不良结局相关(P=.003)而HER2蛋白水平无此关联。
要点
- 血管间隙侵犯、组织学类型和肿瘤大小被验证为强独立预后标志物。
- 高p53蛋白水平独立预测较差生存,但不反映TP53突变状态。
- ERBB2扩增与不良结局相关(P=.003),而HER2蛋白水平无此关联。
核心结论
- 研究支持国际妇产科联盟(FIGO)指南应纳入血管间隙侵犯和肿瘤大小2-4 cm,并认为仔细选择组织学类型对患者风险分层至关重要。
- 高p53水平独立预测较差生存,但不反映宫颈癌中的突变状态。
- ERBB2扩增与较差生存显著相关,而HercepTest检测的HER2蛋白水平无此关联。
- 作者认为,通过优化分层,基于HER2的治疗可能改善宫颈癌治疗。
研究设计与样本
- 研究为基于人群的前瞻性收集宫颈癌队列,共纳入401例患者。
- 从患者病历中收集包括随访评估在内的临床数据。
- 组织病理学数据由一名专家病理学家评估和修订。
- 从292例癌组织制备组织微阵列,通过免疫组化评估p53和HER2蛋白水平。
- 对重叠的宫颈癌新鲜冷冻样本先前进行了HPV分型(n=94)、全外显子组(n=100)和RNA(n=79)测序,结果可用于本分析。
主要发现
- 在临床病理变量中,血管间隙侵犯、组织学类型和肿瘤大小被验证为强独立预后标志物。
- 高p53蛋白水平与侵袭性表型标志物和生存显著相关,在多变量生存分析中亦如此,但不反映TP53突变状态。
- 21%的所有肿瘤中鉴定出高HER2蛋白水平。
- ERBB2扩增与不良结局相关(P=.003);HER2蛋白水平与不良结局无关。
临床怎么用
- 作者认为FIGO指南应纳入血管间隙侵犯和肿瘤大小2-4 cm。
- 作者认为仔细选择组织学类型对患者风险分层至关重要。
- 作者认为通过优化分层,基于HER2的治疗可能改善宫颈癌治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cervical cancer is a major health problem worldwide. Identification of effective clinicopathologic and molecular markers is vital to improve treatment stratification. OBJECTIVES: The purpose of this study was to validate a set of well-defined clinicopathologic features in a large population-based, prospectively collected cervical cancer cohort to support their use in the clinic. Further, we explored p53 and human epidermal growth factor receptor 2 as potential prognostic markers in cervical cancer. STUDY DESIGN: Tissue was collected from 401 patients with cervical cancer. Clinical data that included follow-up evaluations were collected from patient journals. Histopathologic data were evaluated and revised by an expert pathologist. The prognostic impact of selected clinicopathologic variables was analyzed in the whole cohort. Tissue microarrays were prepared from 292 carcinomas, and p53 and human epidermal growth factor receptor 2 protein levels were evaluated by immunohistochemistry. Fresh frozen samples from overlapping cervical carcinomas previously were subjected to human papilloma virus typing (n=94), whole exome (n=100) and RNA (n=79) sequencing; the results were available for our analyses. RESULTS: Among the clinicopathologic variables, vascular space invasion, histologic type, and tumor size were verified as strong independent prognostic markers. High p53 protein levels were associated significantly with markers for aggressive phenotype and survival, also in multivariate survival analysis, but did not reflect TP53 mutational status. High human epidermal growth factor receptor 2 protein levels were identified in 21% of all tumors. ERBB2 amplification was associated with poor outcome (P=.003); human epidermal growth factor receptor 2 protein level was not. CONCLUSIONS: Our findings support that the Féderation Internationale de Gynécologie et d'Obstétrique s guidelines should include vascular space invasion and tumor size 2-4 cm and that careful selection of histologic type is essential for stratification of patient risk groups. High p53 levels independently predict poor survival yet do not reflect mutational status in cervical cancer. Amplified ERBB2 significantly links to poor survival, while HercepTest does not. With optimal stratification, human epidermal growth factor receptor 2-based therapy may improve cervical cancer treatment.
引用
- Halle MK, Ojesina AI, Engerud H, et al. Clinicopathologic and molecular markers in cervical carcinoma: a prospective cohort study. Am J Obstet Gynecol. 2017. PMID: 28599900. doi:10.1016/j.ajog.2017.05.068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。